{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:32:24Z","timestamp":1794022344644,"version":"4.8.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Atopic dermatitis (AD) is a common skin disease, but treatment of this disease has been challenging. Dupilumab is a new biological agent for AD that has been proven to be safe and effective in clinical trials. Although dupilumab was approved for listing in China in June 2020, real-world data about the application of dupilumab in China are lacking. This study aimed to collect and analyze real-world data on dupilumab among Chinese AD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Demographic and clinical data for 116 AD patients receiving dupilumab treatment were reviewed. The Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), Numerical Rating Scale (NRS), Patient Oriented Eczema Measure (POEM), and Dermatology Quality of Life Index (DLQI) of patients were evaluated every 2 weeks from baseline to 16 weeks of treatment. Any adverse events during treatment were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 116 patients in this study, baseline levels of IgE, eosinophils, and LDH were elevated in 62.79% (<jats:italic>n<\/jats:italic> = 86), 45.30% (<jats:italic>n<\/jats:italic> = 86), and 54.20% of patients (<jats:italic>n<\/jats:italic> = 48), respectively. The SCORAD index and POEM, DLQI, and NRS scores were significantly improved in all patients at 2 weeks (<jats:italic>p<\/jats:italic> &amp;lt; 0.0001), 4 weeks (<jats:italic>p<\/jats:italic> &amp;lt; 0.01), and 16 weeks (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). EASI scores also improved significantly in all patients at 2 weeks (<jats:italic>p<\/jats:italic> &amp;lt; 0.01), 4 weeks (&amp;gt; 0.05), and 16 weeks (<jats:italic>p<\/jats:italic> &amp;lt; 0.01). However, 11 patients (9.48%) had no response. IgE and LDH levels (<jats:italic>p<\/jats:italic> &amp;gt; 0.05), Eosinophil counts (<jats:italic>p<\/jats:italic> &amp;lt; 0.01) in blood increased temporarily in the first 4 weeks and then decreased and stabilized during dupilumab treatment. Conjunctivitis was the most common adverse event (2.59%) among the patients. We found that the curative efficacy of dupilumab at 4th weeks was related to the patient\u2019s age and course of disease. Nevertheless, there is no relationship between levels of eosinophils, IgE, LDH and the therapeutic efficacy of dupilumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The real-world data in China showed that dupilumab can effectively treat AD and is well tolerated with a low incidence of adverse events.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.838030","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T23:08:48Z","timestamp":1648508928000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Bingjing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runqiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children.","volume":"34","author":"Wollenberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1080\/09540105.2020.1747406","article-title":"Sensitisation to molecular components in patients with atopic dermatitis, relation to asthma bronchiale and allergic rhinitis.","volume":"31","author":"\u010celakovsk\u00e1","year":"2020","journal-title":"Food Agric Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/09540105.2020.1776224","article-title":"Cluster analysis of molecular components in 100 patients suffering from atopic dermatitis according to the ISAC Multiplex testing.","volume":"31","author":"\u00c8elakovsk\u00e1","year":"2020","journal-title":"Food Agric Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/jdv.15979","article-title":"Development and validation of new diagnostic criteria for atopic dermatitis in children of China.","volume":"34","author":"Cheng","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/exd.13514","article-title":"Atopic dermatitis in diverse racial and ethnic groups-variations in epidemiology, genetics, clinical presentation and treatment.","volume":"27","author":"Kaufman","year":"2018","journal-title":"Exp Dermatol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/srep29751","article-title":"Prevalence of atopic dermatitis in Chinese children aged 1-7 ys.","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.jaci.2015.03.003","article-title":"RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications.","volume":"135","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jaci.2011.05.016","article-title":"Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets.","volume":"128","author":"Fujita","year":"2011","journal-title":"J Allergy Clin Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis.","volume":"138","author":"Werfel","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s0140-6736(20)31286-1","article-title":"Atopic dermatitis.","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/all.14027","article-title":"New biological treatments for asthma and skin allergies.","volume":"75","author":"Eyerich","year":"2020","journal-title":"Allergy."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.anai.2017.10.013","article-title":"Moving toward a more precise treatment of atopic dermatitis.","volume":"120","author":"Ong","year":"2018","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/bjd.18434","article-title":"Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).","volume":"182","author":"Wollenberg","year":"2020","journal-title":"Br J Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial.","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1080\/03007995.2021.1933929","article-title":"Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review.","volume":"37","author":"Iannone","year":"2021","journal-title":"Curr Med Res Opin."},{"key":"B19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s13555-020-00469-6","article-title":"Real-world experience and laboratory monitoring of dupilumab in patients with moderate to severe atopic dermatitis in a tertiary centre.","volume":"11","author":"Kreeshan","year":"2021","journal-title":"Dermatol Ther (Heidelb)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jaad.2003.08.003","article-title":"Guidelines of care for atopic dermatitis, developed in accordance with the American academy of dermatology (AAD)\/American academy of dermatology association \u201cadministrative regulations for evidence-based clinical practice guidelines\u201d.","volume":"50","author":"Hanifin","year":"2004","journal-title":"J Am Acad Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/all.14510","article-title":"Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines.","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061982","article-title":"Retrospective study of dupilumab treatment for moderate to severe atopic dermatitis in Korea: efficacy and safety of dupilumab in real-world practice.","volume":"9","author":"Jang","year":"2020","journal-title":"J Clin Med."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0641","article-title":"Use of dupilumab for 543 adult patients with moderate-to-severe atopic dermatitis: a multicenter, retrospective study.","volume":"32","author":"Nettis","year":"2020","journal-title":"J Investig Allergol Clin Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/all.14080","article-title":"Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry.","volume":"75","author":"Ari\u00ebns","year":"2020","journal-title":"Allergy."},{"key":"B25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40257-021-00597-5","article-title":"Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study.","volume":"22","author":"Patruno","year":"2021","journal-title":"Am J Clin Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.anai.2020.08.002","article-title":"The infectious complications of atopic dermatitis.","volume":"126","author":"Wang","year":"2021","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","article-title":"Racial differences in atopic dermatitis.","volume":"122","author":"Brunner","year":"2019","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization.","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jaad.2020.05.102","article-title":"One-year real-world clinical effectiveness, safety, and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: a single-center retrospective study.","volume":"84","author":"Uchida","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ekir.2020.04.027","article-title":"CKD-associated pruritus: new insights into diagnosis, pathogenesis, and management.","volume":"5","author":"Verduzco","year":"2020","journal-title":"Kidney Int Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.3748\/wjg.v21.i5.1404","article-title":"Jaundice associated pruritis: a review of pathophysiology and treatment.","volume":"21","author":"Bassari","year":"2015","journal-title":"World J Gastroenterol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.jaad.2020.02.029","article-title":"Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: a retrospective cohort study.","volume":"82","author":"Jo","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/ijd.14573","article-title":"Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients\u2019 records.","volume":"59","author":"Wang","year":"2020","journal-title":"Int J Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.18163","article-title":"Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study.","volume":"181","author":"Uchida","year":"2019","journal-title":"Br J Dermatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.","volume":"81","author":"Faiz","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials.","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/bjd.18179","article-title":"Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data.","volume":"182","author":"de Wijs","year":"2020","journal-title":"Br J Dermatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jaad.2019.10.010","article-title":"Off-label use of dupilumab for pediatric patients with atopic dermatitis: a multicenter retrospective review.","volume":"82","author":"Igelman","year":"2020","journal-title":"J Am Acad Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.838030\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T23:08:58Z","timestamp":1648508938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.838030\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":38,"alternative-id":["10.3389\/fmed.2022.838030"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.838030","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]},"article-number":"838030"}}